Compare KVHI & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVHI | VTVT |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.7M | 144.0M |
| IPO Year | 1996 | 2015 |
| Metric | KVHI | VTVT |
|---|---|---|
| Price | $9.24 | $37.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $53.00 |
| AVG Volume (30 Days) | ★ 129.7K | 38.5K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,622,000.00 | N/A |
| Revenue This Year | $28.90 | N/A |
| Revenue Next Year | $31.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.82 | N/A |
| 52 Week Low | $4.85 | $14.00 |
| 52 Week High | $9.49 | $44.00 |
| Indicator | KVHI | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 66.77 | 51.00 |
| Support Level | $5.29 | $33.91 |
| Resistance Level | $9.41 | $42.12 |
| Average True Range (ATR) | 0.45 | 2.60 |
| MACD | -0.05 | -0.18 |
| Stochastic Oscillator | 78.39 | 34.53 |
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.